Ipca Laboratories posts 14% domestic formulations growth, keeps FY27 guidance unchanged
AI Summary- Ipca Laboratories reported domestic formulations growth and retained its FY27 financial guidance.
- Domestic formulations reached Rs 1,157 crore, while consolidated EBITDA margin rose to 22.97%.
- The company held approximately Rs 700 crore in cash and expected rupee loans to fall further by year-end.